Early Systemic Failure After Preoperative Chemoradiotherapy for the Treatment of Patients With Rectal Cancer

Article information

Ann Coloproctol. 2019;35(2):94-99
Publication date (electronic) : 2019 April 30
doi : https://doi.org/10.3393/ac.2018.08.28
Department of Surgery, Korea University College of Medicine, Seoul, Korea
Correspondence to: Se-Jin Baek, M.D. Department of Surgery, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 02841, Korea Tel: +82-2-920-6284, Fax: +82-2-928-1631 E-mail: xezin@korea.ac.kr

This study was presented as a poster at the Annual Scientific Meeting of The American Society of Colon & Rectal Surgeons (ASCRS), April 30–May 4, 2016, Los Angeles, CA, USA.

Received 2018 April 21; Accepted 2018 August 28.



Distant metastasis can occur early after neoadjuvant chemoradiotherapy (CRT) in patients with rectal cancer. This study was conducted to evaluate the clinical characteristics of patients who developed early systemic failure.


The patients who underwent neoadjuvant CRT for a rectal adenocarcinoma between June 2007 and July 2015 were included in this study. Patients who developed distant metastasis within 6 months after CRT were identified. We compared short- and long-term clinicopathologic outcomes of patients in the early failure (EF) group with those of patients in the control group.


Of 107 patients who underwent neoadjuvant CRT for rectal cancer, 7 developed early systemic failure. The lung was the most common metastatic site. In the EF group, preoperative carcinoembryonic antigen was higher (5 mg/mL vs. 2 mg/mL, P = 0.010), and capecitabine as a sensitizer of CRT was used more frequently (28.6% vs. 3%, P = 0.002). Of the 7 patients in the EF group, only 4 underwent a primary tumor resection (57.1%), in contrast to the 100% resection rate in the control group (P < 0.001). In terms of pathologic outcomes, ypN and TNM stages were more advanced in the EF group (P < 0.001 and P = 0.047, respectively), and numbers of positive and retrieved lymph nodes were much higher (P < 0.001 and P = 0.027, respectively).


Although early distant metastasis after CRT for rectal cancer is very rare, patients who developed early metastasis showed a poor nodal response with a low primary tumor resection rate and poor oncologic outcomes.


Over the last several decades, preoperative chemoradiotherapy (CRT) has been accepted as a standard treatment for patients with locally advanced rectal cancer because it can reduce local recurrence postoperatively and enable sphincter-saving surgery in some patients who had been ineligible for the procedure before CRT [1, 2]. National Comprehensive Cancer Network guidelines recommend preoperative radiotherapy or CRT for all patients with rectal cancer suspected to be greater than stage T3 or with lymph node (LN) metastasis on preoperative evaluation [3].

Concern for failure of systemic control of the disease during CRT remains an issue in the treatment of patients with cancer because radiotherapy only involves local treatment of the disease and rectal cancer in patients who are eligible for preoperative radiotherapy is locally advanced. Moreover, a long period of about three to four months is typical between diagnosis and surgery. Thus, many other chemotherapy regimens added to fluorouracil-based CRT have been suggested in an effort to enhance systemic control during CRT or within the window from radiotherapy to surgery [4, 5].

Nevertheless, reports of early distant metastasis during or after preoperative CRT are rare. For that reason, we conducted this study to evaluate the incidence and the clinical significance of early distant metastasis after preoperative CRT in patients with rectal cancer and to provide data that will be useful in determining the evaluation or follow-up protocol for patients whose risk for early distant metastasis is high.


Patient selection and classification

The medical records of patients who had undergone long-course CRT with neoadjuvant intention for rectal cancer at Korea University Anam Hospital, Seoul, Korea, between June 2007 and July 2015, were retrospectively reviewed. This study was approved by the Institutional Review Board of Korea University Anam Hospital (IRB No. 2018AN0158), and all patients provided written informed consent. Patients who had primary rectal cancer with a pathologically proven adenocarcinoma within 15 cm of the anal verge, subdivided as lower (<5 cm), mid (5–10 cm), and upper (>10 cm) rectum, were enrolled in this study. Patients who developed distant metastasis within 6 months after completion of CRT were assigned to the early systemic failure group (the EF group). All other patients were assigned to the control group.

Preoperative evaluation and preoperative CRT

All patients were evaluated preoperatively by using physical examination, total colonoscopy, abdominopelvic computed tomography (CT), chest CT, pelvic magnetic resonance imaging, and routine laboratory tests including tumor markers. Based on these studies, patients without distant metastasis were considered for preoperative CRT.

Preoperative CRT has been performed selectively at our institution; patients with resectable locally advanced rectal cancer including T3 stage and patients with LNs suggesting metastasis including the total mesorectal excision (TME) plane were considered for surgery without preoperative CRT [6]. The indications for preoperative CRT at our hospital were as follows: T4, circumferential resection margin involved or threatened, or suggestive metastasis of lateral pelvic LN, defined as a LN beyond the TME plane such as iliac and obturator LNs, on preoperative staging. Exclusion criteria in this study were as follows: radiotherapy for anal cancer or for recurrent rectal cancer; preoperative short-course radiotherapy or postoperative radiotherapy; initial distant metastasis; no restaging work-up after CRT preoperatively or no appropriate follow-up; or preoperative exposure to chemotherapy regimens other than 5-fluorouracil (5-FU) or capecitabine as a radiosensitizer, such as with oxaliplatin, irinotecan, or a target agent.

Patients were treated with neoadjuvant chemoradiation (5,040 cGy in 28 fractions) for 5–6 weeks, with intravenous or oral 5-FU (tegafur) or oral capecitabine as a radiosensitizer. Each patient was evaluated by restaging 8–10 weeks later for final decision; then, surgery was performed in most patients unless certain problems, such as distant metastasis or a locally refractory response, developed.

Adjuvant therapy and patient follow-up

In patients with stage II disease with risk factors or stage III disease postoperatively, oxaliplatin-based adjuvant chemotherapy was performed for 8–12 cycles. In patients who underwent chemotherapy, laboratory tests, including carcinoembryonic antigen (CEA) and abdominopelvic and chest CT, were performed at 3- to 4-cycle intervals during chemotherapy, and other examinations, such as sigmoidoscopy or total colonoscopy and positron emission tomography (PET)-CT, were added when necessary. After chemotherapy, follow-up examinations were carried out at 3-month intervals during the first 2 years postoperatively, at 6-month intervals until 5 years after surgery, and then annually if no evidence of recurrence was found.

Statistical analysis

Data for the early failure (EF) and the control groups were compared in terms of patient demographics, tumor characteristics, operative and postoperative outcomes, pathologic results, and oncologic outcomes. Descriptive results are presented as medians for continuous outcomes and as frequencies and percentages for categorical outcomes. For nonparametric statistics, Mann-Whitney U-test was used to compare continuous variables, and the chi-square test or Fisher exact test was applied for categorical variables. Five-year overall survival (OS) and recurrence-free survival (RFS) were analyzed using the Kaplan-Meier method, and comparison of survival between groups was performed by using the log-rank test. Statistical analyses were performed using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). A P-value < 0.05 was considered statistically significant.


During the study period, 388 patients with rectal cancer received radiotherapy. Seven patients received radiotherapy for anal cancer or recurrent rectal cancer, 160 received preoperative short-course radiotherapy or postoperative radiotherapy, 72 were found to have an initial distant metastasis, 39 had no restaging work-up or follow-up, and 3 had preoperative exposure to other chemotherapy. Of these, 107 patients were enrolled in the study, and 7 developed early distant metastasis. In the patients with early distant metastasis, the lung was the most common site of distant metastasis (4 patients), followed by bone (3 patients), liver (1 patient), and intramural metastasis of the anal canal (1 patient) (Table 1). The median duration for metastasis was 78.1 days.

Detailed description of patients who developed early systemic failure

Patient demographics are detailed in Table 2. No significant differences were found between the EF and the control groups in terms of age, sex, body mass index, level of tumor location, initial clinical T and N stage, or tumor size. In addition, the duration and the doses of radiotherapy were similar. Preoperative CEA was significantly higher in the EF group than in the control group (5 mg/mL vs. 2 mg/mL, P = 0.010). Also, most patients in the control group received intravenous or oral 5-FU as a radiosensitizer, but patients who used capecitabine were relatively more frequent (EF: 28.6% vs. control: 3%, P = 0.002) in the EF group.

Patient demographics and tumor characteristics

Only 4 of the 7 patients (57.1%) with early distant metastasis underwent a resection of the primary rectal lesion. Operative and postoperative outcomes in the patients who received a resection are compared in Table 3. The resection rate was significant lower in the EF group at 57.1% compared to the control group at 100% (P < 0.001). The median duration from CRT to surgery was significantly longer in the EF group (68.0 days vs. 54.7 days, P = 0.027). No significant differences were found between the groups in terms of type of approach, procedure, rate of sphincter-saving surgery, emergency surgery, operative time, or estimated blood loss. Postoperative morbidity and hospital stay were also similar between the 2 groups.

Operative outcomes and postoperative course

Among the postoperative pathologic results, the groups were not different in terms of ypT stage and tumor size (Table 4). However, both ypN stage and TNM stage were advanced in the EF group (P < 0.001 and P = 0.034, respectively), and the numbers of positive and retrieved LNs were significantly higher in the EF group (P = 0.006 and P = 0.017, respectively).

Pathologic outcomes

Adjuvant or palliative chemotherapy or the patients and their oncologic outcomes are described in Table 5. In the control group, local recurrence developed in 9 patients, distant metastasis in 15 patients, and disease recurrence in 23 patients. In the EF group, one patient experienced a local recurrence other than distant metastasis. The median follow-up duration was 11.2 months in the EF group and 33 months in the control group (P < 0.001). A significant difference between the 2 groups was found for RFS (P < 0.001), but not OS (P = 0.731).

Oncologic outcomes


In our study, early distant metastasis developed in 6.5% of the patients who had received preoperative CRT. This is a very rare report for early metastasis after preoperative CRT. Kang et al. [7] reported no patients who developed new metastatic lesions before or during surgery in a study comparing open and laparoscopic surgery for mid or low rectal cancer after neoadjuvant CRT. Bujko et al. [8] did not directly report the rate of early distant metastasis in their study comparing long-term oncologic outcomes of short-course RT and long-course CRT for patients with rectal cancer; instead, they reported that 140 of the 155 patients allocated to the short-course RT group and 143 of the 157 patients allocated to the CRT group had no distant metastasis at the time of surgery and were alive 30 days after surgery.

We identified the clinical characteristics of patients who developed early distant metastasis. Patients developing early metastasis had a significantly lower rate of primary tumor resection (57.1%) compared to the control group, possibly because patients with distant metastasis in the absence of symptoms frequently receive palliative chemotherapy without surgery. In addition, the time from CRT to surgery may have been longer in the EF group due to the design of new treatment plans for unexpected distant metastasis.

In this study, capecitabine as a radiosensitizer was frequently used in the EF group. The result could be misinterpreted to mean that capecitabine has weaker systemic effects than 5-FU, which differs from the results of previous studies. In general, capecitabine not only shows better oncologic outcomes than 5-FU at a systemically effective dose as an adjuvant treatment (1,250 mg/m2 twice daily), but its oncologic superiority continues at a lower dose (825 mg/m2 twice daily) as a radiosensitizer for CRT [9, 10]. Because the results in our study may have statistical bias due to the small number of patients in the EF group, further study including a larger number of patients is needed.

The lung was the most common site of distant metastasis in the EF group, which was unexpected given that, in general, the liver is the most common metastatic site of colorectal cancer. This difference might be attributed to the locations of the tumor levels in the lower rectum, which were a median of 4 cm above the anal verge. Generally, lymphatic drainage of the mid to lower rectum passes through the lateral pathway and drains directly to the lung [11, 12]. Bone metastasis was also common, second to lung metastasis, and both of these metastases are very aggressive, with short life expectancy [13, 14]. Thus, the metastatic lesions in the EF group indicated their potential aggressiveness, which was also represented by poor nodal response to preoperative CRT.

The possibility should be considered that early distant metastasis may arise from metastasis missed on initial imaging studies for work-up. Abdominopelvic and chest CT, as well as PET-CT, can be read as false negative for a distant metastasis with a small size [15, 16]. In particular, indeterminate nodules are common on chest CT, and pulmonary metastasis can be difficult to assess [6, 17]. Radiologic methods are limited in their ability to detect microscopic metastases. Accordingly, a relevant radiological diagnosis should be a prerequisite for formulating an appropriate treatment plan, as well as a follow-up imaging work-up.

The challenge remains to identify early which patients will experience a poor local response to CRT and develop a distant metastasis. We found no significant differences in any of the patients’ demographics or tumor characteristics between the EF and the control groups. If a meaningful intrinsic factor associated with the response to CRT, such as a gene expression profile, could be found, that factor could help in planning neoadjuvant therapy. However, studies on predictive factors are lacking. Some studies have suggested possible factors, but most of these remain at the experimental level [18, 19].

Accurate predictions of the responses to CRT or to craft tailored treatments are still not possible. The strategy of avoiding CRT due to concerns for early systemic failure may cause more injury than good for patients given that the rate of early systemic failure was very low in our study, at 6.5%. Therefore, a realistic alternative would be to conduct intensive follow-up for early detection of a distant metastasis during CRT, although debate is still ongoing regarding the utility of restaging images after neoadjuvant treatment for changing treatment strategy [20, 21]. Along with initial studies before CRT and preoperative restaging work-ups after CRT, additional abdominopelvic and chest CT could be added during the interval from 8 to 10 weeks after CRT.

This study had some limitations. First, it was a retrospective analysis with several biases and a small number of patients in the EF group. In particular, many patients received short-course radiotherapy at our institution and were excluded from this study. The results might have been different if they had also received CRT. Above all, evaluating the risk factors for early systemic failure was difficult because of the large difference in the numbers of patients between the EF and the control groups. Moreover, molecular biomarkers, such as epidermal growth factor receptor, K-ras/N-ras, microsatellite instabilities, and caudal type homeobox-2, were not analyzed due to insufficient data. Nevertheless, our study is very valuable because data on the clinical characteristics of early distant metastasis after CRT are rare.

In conclusion, unlike our concern, in this study, early distant metastasis rarely developed after CRT for the treatment of patients with rectal cancer. Patients who developed an early metastasis also had poor nodal responses to CRT, with low primary tumor resection rates and very poor oncologic results. For early detection and treatment, intensive follow-up imaging work-ups can be considered during the period between CRT and surgery. Furthermore, additional study is needed to identify intrinsic factors helpful for predicting the responses of patients to CRT and for tailoring treatment.


No potential conflict of interest relevant to this article was reported.


1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731–40.
2. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620–5.
3. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, et al. Rectal cancer. J Natl Compr Canc Netw 2012;10:1528–64.
4. Glynne-Jones R, Falk S, Maughan TS, Meadows HM, Sebag-Montefiore D. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Br J Cancer 2007;96:551–8.
5. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015;16:979–89.
6. Baek SJ, Kim SH, Kwak JM, Cho JS, Shin JW, Amar AH, et al. Indeterminate pulmonary nodules in rectal cancer: a recommendation for follow-up guidelines. J Surg Oncol 2012;106:481–5.
7. Kang SB, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 2010;11:637–45.
8. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:1215–23.
9. Yoney A, Isikli L. Preoperative chemoradiation in locally advanced rectal cancer: a comparison of bolus 5-fluorouracil/leucovorin and capecitabine. Saudi J Gastroenterol 2014;20:102–7.
10. Kim DY, Jung KH, Kim TH, Kim DW, Chang HJ, Jeong JY, et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007;67:378–84.
11. Pihl E, Hughes ES, McDermott FT, Johnson WR, Katrivessis H. Lung recurrence after curative surgery for colorectal cancer. Dis Colon Rectum 1987;30:417–9.
12. Scheele J, Altendorf-Hofmann A, Stangl R, Gall FP. Pulmonary resection for metastatic colon and upper rectum cancer. Is it useful? Dis Colon Rectum 1990;33:745–52.
13. Baek SJ, Hur H, Min BS, Baik SH, Lee KY, Kim NK. The characteristics of bone metastasis in patients with colorectal cancer: a long-term report from a single institution. World J Surg 2016;40:982–6.
14. Khattak MA, Martin HL, Beeke C, Price T, Carruthers S, Kim S, et al. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 2012;11:247–54.
15. Zerhouni EA, Rutter C, Hamilton SR, Balfe DM, Megibow AJ, Francis IR, et al. CT and MR imaging in the staging of colorectal carcinoma: report of the Radiology Diagnostic Oncology Group II. Radiology 1996;200:443–51.
16. Lu YY, Chen JH, Ding HJ, Chien CR, Lin WY, Kao CH. A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET/CT. Nucl Med Commun 2012;33:1127–33.
17. Quyn AJ, Matthews A, Daniel T, Amin AI, Yalamarthi S. The clinical significance of radiologically detected indeterminate pulmonary nodules in colorectal cancer. Colorectal Dis 2012;14:828–31.
18. He HL, Lee YE, Shiue YL, Lee SW, Lin LC, Chen TJ, et al. PLA2G2A overexpression is associated with poor therapeutic response and inferior outcome in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy. Histopathology 2015;66:991–1002.
19. Lee YE, He HL, Shiue YL, Lee SW, Lin LC, Wu TF, et al. The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy. Tumour Biol 2015;36:7675–83.
20. Ayez N, Alberda WJ, Burger JW, Eggermont AM, Nuyttens JJ, Dwarkasing RS, et al. Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary? Ann Surg Oncol 2013;20:155–60.
21. Jaffe TA, Neville AM, Bashir MR, Uronis HE, Thacker JM. Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? Colorectal Dis 2013;15:e654–8.

Article information Continued

Table 1.

Detailed description of patients who developed early systemic failure

Patient No. Clinical stage Clinical tumor size (cm) AV (cm) Preoperative CEA (ng/mL) Resection of primary tumor Interval from RT to operation (day) Metastatic lesion Interval from RT to metastasis (day) Treatment for metastatic lesion Follow-up duration (mo)
1 cT3N2 6.1 6 11.21 No NA Anal canal, pelvic bone 56 Chemotherapy 3.6
2 cT4N2 4 2 5.6 No NA Pelvic bone 32 None 7.0
3 cT3N2 6.1 8 1.40 Yes 70 Lung, liver 49 Chemotherapy 11.2
4 cT3N0 3.4 3 - Yes 66 Lung 91 Chemotherapy VATS 14.5
5 cT3N2 5.2 4 13.60 Yes 59 Lung 79 Chemotherapy VATS 12.1
6 cT2N1 4 2 4.62 Yes 77 Multiple bone 144 Chemotherapy 8.8
7 cT3N2 5 7 3.30 No NA Lung 96 Chemotherapy 17.8

AV, anal verge; CEA, carcinoembryonic antigen; RT, radiotherapy; NA, not applicable; VATS, video-assisted thoracoscopic surgery.

Table 2.

Patient demographics and tumor characteristics

Characteristic Early failure group (n = 7) Control group (n = 100) P-value
Age (yr) 59 60 0.955
Sex, male : female 4 : 3 71 : 29 0.444
Mean body mass index (kg/m2) 21 23 0.116
Mean anal verge (cm) 4 5 0.520
Mean preoperative CEA (ng/mL) 5 2 0.010
cT stage 0.431
 cT2 1 (14.3) 5 (5)
 cT3 5 (71.4) 75 (75)
 cT4 1 (14.3) 20 (20)
cN stage 0.850
 cN0 1 (14.3) 11 (11)
 cN1 1 (14.3) 26 (26)
 cN2 5 (71.4) 63 (63)
Mean clinical tumor size (cm) 5 5 0.582
Median RT duration (day) 39 39 0.770
Mean RT dose (cGy) 5,040 5,040 0.591
Radiosensitizer 0.002
 IV 5-FU 4 (57.1) 90 (90)
 Oral 5-FU (tegafur) 1 (14.3) 7 (7)
 Capecitabine 2 (28.6) 3 (3)

Values are presented as number (%) unless otherwise indicated.

CEA, carcinoembryonic antigen; RT, radiotherapy; IV, intravenous; 5-FU, 5-fluorouracil.

Table 3.

Operative outcomes and postoperative course

Variable Early failure group (n = 7) Control group (n = 100) P-value
Resection of primary tumor 4 (57.1) 100 (100) <0.001
 Duration to surgery (day) 66 55 0.027
 Type of approach 0.471
  Robot 4 (100) 56 (56)
  Laparoscopy 0 (0) 36 (36)
  Open 0 (0) 5 (5)
  Conversion 0 (0) 3 (3)
 Procedure 0.268
  LAR 1 (25) 56 (56)
  ISR 2 (50) 34 (34)
  APR 1 (25) 7 (7)
  Hartmann procedure 0 (0) 3 (3)
 Sphincter-saving surgery 3 (75) 90 (90) 0.344
 Emergency surgery 0 (0) 1 (1) 0.843
 Mean operative time (min) 353 285 0.114
 Mean estimated blood loss (mL) 0 0 0.132
 Morbidity 3 (75) 34 (34) 0.098
  Anastomotic leakage 0 (0) 10 (10) 0.508
 Median preoperative hospital stay (day) 14 9 0.233

Values are presented as number (%) unless otherwise indicated.

LAR, low anterior resection; ISR, intersphincteric resection; APR, abdominoperineal resection.

Table 4.

Pathologic outcomes

Variable Early failure group that underwent resection (n = 4) Control group (n = 100) P-value
ypT stage 0.104
 ypT0 0 (0) 14 (14)
 ypT1 0 (0) 3 (3)
 ypT2 0 (0) 23 (23)
 ypT3 2 (50) 54 (54)
 ypT4 2 (50) 6 (6)
ypN stage <0.001
 ypN0 0 (0) 65 (65)
 ypN1 1 (25) 28 (28)
 ypN2 3 (75) 7 (7)
Mean positive LNs 6 0 0.006
Mean retrieved LNs 30 13 0.017
ypTNM stage
 0 : 1 : 2 : 3 : 4 0 : 0 : 0 : 0 : 4 13 : 18 : 35 : 34 : 0 0.034
Mean tumor size after CRT (cm) 2 3 0.175
Mean PRM (cm) 22 23 0.686
Mean DRM (cm) 2 2 0.577
Mandard regression grade
 1 : 2 : 3 : 4 : 5 0 : 0 : 1 : 3 : 0 5 : 3 : 10 : 16 : 0 (n = 34) 0.240

Values are presented as number (%) unless otherwise indicated.

LN, lymph node; CRT, chemoradiotherapy; PRM, proximal resection margin; DRM, distal resection margin.

Table 5.

Oncologic outcomes

Variable Early failure group (n = 7) Control group (n = 100) P-value
Adjuvant chemotherapy - NA
 No - 19 (19)
 FOLFOX - 42 (42)
 IV 5-FU - 23 (23)
 Oral 5-FU (tegafur) - 9 (9)
 Capecitabine - 7 (7)
Palliative chemotherapy - NA
 No 1 (14.3) -
 FOLFOX 3 (42.9) -
 Capecitabine 1 (14.3) -
 FOLFIRI + bevacizumab 2 (28.6) -
Disease recurrence 7 (100) 23 (23)
 Local recurrence 1 (14.3) 9 (9)
 Distant metastasis 7 (100) 15 (15)
Mean follow-up (mo) 11.2 33.0 0.001

NA, not applicable; FOLFOX, oxaliplatin-based chemotherapy; IV, intravenous; 5-FU, 5-fluorouracil; FOLFIRI, irinotecan-based chemotherapy.